Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia
The Medical Letter on Drugs and Therapeutics · 2025
DOI: 10.58347/tml.2025.1727e ↗Kurz gefasst
Leserbrief in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2025. Hauptthemen laut MEDLINE: Choline, Diazoxide, Prader-Willi Syndrome, Hyperphagia.
Abstract (Originalsprache)
The FDA has approved diazoxide choline extended-release tablets (Vykat XR – Soleno Therapeutics) for treatment of hyperphagia in patients ≥4 years old with Prader-Willi syndrome. Diazoxide choline is the first drug to be approved in the US for this indication. Diazoxide oral suspension (Proglycem) has been available for years for management of symptomatic hypoglycemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2025). Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2025.1727e
Vancouver
Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia. The Medical Letter on Drugs and Therapeutics. 2025. doi:10.58347/tml.2025.1727e
BibTeX
@article{euvimed2025,
title = {Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2025},
doi = {10.58347/tml.2025.1727e}
}
EUVIMED